期刊文献+

成人型多囊肾病149例肾功能危险因素分析 被引量:1

Analysis on aggravating factors in renal function of 149 patients with autosomal dominant polycystic kidney disease
下载PDF
导出
摘要 目的探讨常染色体显性遗传性多囊肾病(ADPKD)患者临床特点及导致肾功能损害进展加速的因素。方法回顾性分析149例ADPKD患者临床资料,按照年龄、病程、血压、血尿程度、血脂情况、肾脏体积、24小时尿蛋白定量、是否合并泌尿系结石、有无家族史进行分组,分析上述因素对肾功能损害进展的影响。结果血尿、高血压、蛋白尿、肾功能异常、合并多囊肝是本病最常见的临床表现。病程年限越长(≥5年)、血压越高(≥160/100 mmHg)、肾脏体积越大(≥300 cm×300 cm×300 cm),肾功能损害越重(P<0.05);伴有血尿、蛋白尿、高脂血症者肾功能损害较无上述症状者更严重(P<0.05)。结论 ADPKD患者肾功能恶化与年龄、家族史无明显关系,但与病程延长、血压增高、蛋白尿、脂质代谢紊乱、血尿、肾脏体积大小密切相关,临床上应早期发现、积极治疗上述因素,尽量延缓多囊肾肾功能恶化的进程。 Objective To analyze clinical characteristics and factors which accelerate the progress of renal dysfunction in patients with autosomal dominant polycystic kidney disease(ADPKD).Methods The clinical data including various complications in 149 patients with ADPKD were retrospectively analyzed.All patients were divided into different groups according to age,disease duration,blood pressure,hematuria level,blood lipid,renal volume,24-hour urine protein,the urinary stones and family history.We analyzed the relationship between the above-mentioned factors with the renal function.Results Hematuria,hypertension,proteinuria,renal dysfunction,the merged polycystic liver disease were the most common clinical manifestations.The longer the duration of disease,the higher blood pressure;the greater kidney volume,the more severe renal dysfunction(P〈0.05).The renal dysfunction was heavier in patients accompanied by hematuria,proteinuria or hyperlipidemia than in the non-above mentioned symptoms subjects(P〈0.05).Conclusion There is no significant relationship between renal function with age,family history,but the blood pressure,proteinuria,disease duration,lipid metabolism disorder,hematuria,kidney volume size are closely related to renal function.We should detect and treat these factors earlier in order to slow down the process of renal function deterioration in polycystic kidney disease.
出处 《临床荟萃》 CAS 2010年第16期1401-1404,1407,共5页 Clinical Focus
关键词 多囊肾 常染色体显性 肾功能试验 危险因素 polycystic kidney autosomal dominant kidney function tests risk factors
  • 相关文献

参考文献18

  • 1Boucher C,Sandlford R. Autosomal dominant polycystic kidney disease (ADPKD, MIM 173900, PKD1 and PKD2 genes, protein products known as polycystin-1 and polycystin-2) [J]. Eur J Hum Genet,2004,12(5) :347-354.
  • 2梅长林,戴兵.多囊肾病慢性进展的分子发病机制及治疗对策[J].中国实用内科杂志,2007,27(1):53-55. 被引量:10
  • 3Romao EA, Moyses Neto M, Teixeira SR, et al. Renal and extrarenal manifestations of autosomal dominant polycystie kidney disease[J]. Braz J Med Bio Res, 2006,39 (4): 533-538.
  • 4Ravine D, Gibson RN, Walker RG, et al. Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1 [J]. Lancet, 1994,343 ( 8901 ) : 824- 827.
  • 5Fick-Brosnahan GM, Belz MM, McFann KK, et al. Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease : a longitudinal study[J]. Am J Kidney Dis, 2002,39 (6) : 1127- 1134.
  • 6Eo HS,Lee J G, Ahn C,et al. Three novel mutations of the PKD1 gene in Korean patients with autosomal dominant polyeystic kidney disase [J]. Clin Genet, 2002,62 ( 2 ) : 169-174.
  • 7Gomez PF, Garcia-Cosmes P, Becerra LG, et al. Clinical analysis of a population with autosomal dominant polycystic kidney disease[J]. Nefrologia, 2010,30 ( 1 ) : 87-94.
  • 8Qian Q, Harris PC, Torres VE. Treatment prospects tor autosomal dominant polycystic kidney disease[J]. Kidney Int, 2001,59(6) : 2005-2022.
  • 9Idrizi A, Barbullushi M, Petrela E, et al. The influence of renal manifestations to the progression of autosomal dominant polycystie kidney disease[J]. Hippokratia, 2009,13 (3) : 161-164.
  • 10Brunner FP, Thiel G, Hermle M, et al. Long-term enalapril and verpamil in rats with reduced renal mass[J]. Kidney Int, 1989, 36(6) :969-977.

二级参考文献15

  • 1梅长林,王文靖.多囊肾病的诊断及治疗进展[J].中国实用内科杂志,2005,25(11):969-971. 被引量:12
  • 2梅长林,戴兵.常染色体显性多囊肾病:挑战与策略[J].中华肾脏病杂志,2005,21(11):636-637. 被引量:13
  • 3戴兵,刘亚伟,梅长林.纤毛与肾囊肿性疾病[J].中华肾脏病杂志,2006,22(2):129-132. 被引量:3
  • 4Dai B,Mei CL.ADPKD Research in China.Chin Med J (Eng)[J].In press.
  • 5Ruggenenti P,Remuzzi A,Ondei P,et al.Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease[J].Kidney Int,2005,68 (1):206-216.
  • 6Schrier RW,McFann KK,Johnson AM.Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease[J].Kidney Int,2003,63 (2):678-685.
  • 7Jafar TH,Stark PC,Schmid CH,et al.ACE Inhibition in Progressive Renal Disease (AIPRD) Study Group.The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease[J].Kidney Int,2005,67 (1):265-271.
  • 8Nauli SM,Alenghat FJ,Luo Y,et al.Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells[J].Nat Genet,2003,33 (2):129-137.
  • 9Gattone VH,Wang X,Harris PC,et al.Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist[J].Nat Med,2003,9 (10):1323-1326.
  • 10Bennett WM.V2 receptor antagonists in cystic kidney diseases:an exciting step towards a practical treatment[J].J Am Soc Nephrol,2005,16 (4):838-839.

共引文献14

同被引文献2

引证文献1

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部